


## L-Tyrosine-4-<sup>13</sup>C

<b>Cat. No.:</b>	HY-N0473S5
<b>CAS No.:</b>	81201-90-3
<b>Molecular Formula:</b>	C <sub>8</sub> <sup>13</sup> CH <sub>11</sub> NO <sub>3</sub>
<b>Molecular Weight:</b>	182.18
<b>Target:</b>	Endogenous Metabolite; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Others
<b>Storage:</b>	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 10.87 mg/mL (59.67 mM; ultrasonic and warming and adjust pH to 9 with NaOH and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	5.4891 mL	27.4454 mL	54.8908 mL
5 mM	1.0978 mL	5.4891 mL	10.9782 mL
10 mM	0.5489 mL	2.7445 mL	5.4891 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

L-Tyrosine-4-<sup>13</sup>C is the <sup>13</sup>C-labeled L-Tyrosine. L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA